
BioVenture VoiCes with Chris Garabedian
BiotechTVAudio
- Format:
- Podcast
- New episodes:
- Every two weeks
- Typical length:
- about 1 hour 10 minutes
- Latest episode:
About this show
Hosted by Chris Garabedian, meet the leading Voices in the BioVenture community and hear their insights and perspectives on the challenges and successes with VC investing.
Covers: biotech, venture capital, life sciences investing, healthcare investing, biopharma industry, startup funding, medical devices, precision oncology
Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
This podcast features conversations with leading venture investors in biotech about the challenges and successes of backing companies. Recent episodes cover corporate venture investing with Sanofi Ventures' Jason Hafler and early biotech history with Third Rock Ventures' Bob Tepper.
Cosmos
Similar in subject
- Project Medtech
Both cover: medical devices, startup funding, venture capital - Cell & Gene: The Podcast
Both cover: biopharma industry, precision oncology - The Biotech Startups Podcast
Both cover: biotech, venture capital
Similar shows
Explore more
Episodes
Episode 32: ARCH Venture Partners' Bob Nelsen
· 1 hr 15 min
While describing his early life in Washington and formative years at the University of Chicago that led to the founding of ARCH, he shares his thoughts on leadership, risk taking, changes he thinks are need to keep the United States competitive in life sciences, and his belief in AI's promise to transform our industry.
Not rated yetEpisode 31: Polaris Partners' Amy Schulman
· 1 hr 2 min
She describes her career beginnings as a lawyer, which led to general counsel and business unit head roles at Pfizer, and then joining the VC world at Polaris Partners (at Bob Langer's urging). She discusses the firm's investment philosophy, the nuances behind how companies choose lead assets, and the cycles biotech has been through over the last ten years. Plus, other roles she currently serves, including being the chair of Alnylam.
Not rated yetEpisode 30: F-Prime Capital Senior Managing Partner Stephen Knight
· 1 hr 0 min
He describes his early life and career experiences at Bell Labs, consulting work, and EPIX Pharmaceuticals before landing in his true interest, venture capital. Dr. Knight describes the foresight of Fidelity to focus on life sciences in its early days, and F-Prime's investing philosophy today.
Not rated yetEpisode 29: Averin Managing Partner David Berry
· 1 hr 19 min
He describes his early life and education, 18 years of company building at Flagship Pioneering, founding Averin (previously called Bedford Bridge) with his brother, and investing at the intersection of healthcare and technology.
Not rated yetEpisode 28: Hatteras Venture Partners' Clay Thorp
· 1 hr 0 min
Clay Thorp describes his early education and becoming a business partner to his brother on a genomics startup. He describes the genesis of Hatteras, the history and strengths of the life sciences ecosystem in the North Carolina area, and his philosophy of backing founders.
Not rated yetEpisode 27: Avalon Bioventures' Jay Lichter
· 1 hr 3 min
Jay Lichter describes his roots growing up in Chicago, Yale, and an early career role at DuPont Merck before getting a call from Kevin Kinsella to try the world of venture at Avalon. Since that pivotal move, he describes numerous companies he either operated or funded, leading to his work today at Avalon Bioventures.
Not rated yetEpisode 26: venBio's Corey Goodman
· 1 hr 21 min
Corey Goodman shares learnings for his career in biotech, including working in academia, biotech, pharma, and as a venture capital investor. He describes the unique learnings from all of them and why he is thankful that he has experienced these different components of life sciences.
Not rated yetEpisode 25: Atlas Venture's Bruce Booth
· 1 hr 18 min
Bruce Booth discusses his education and early career, the structure of Atlas and the types of investments it makes, investing in assets vs platforms, and more.
Not rated yetEpisode 24: Samsara Biocapital's Srini Akkaraju
· 1 hr 12 min
The Founder & Managing Partner of Samsara Biocapital, Dr. Akkaraju describes his early move from Standford to industry and various investment firms he worked for before founding Samsara in 2016. He discusses how the firm invests in all stages of life sciences companies and why he believes patience is a key virtue.
Not rated yetEpisode 23: a16z's Vineeta Agarwala
· 1 hr 20 min
Still a practicing physician today, Vineeta Agarwala describes her educational background and early career, including experiences at the Broad Institute, Flatiron Health, and GV (Google Ventures). She talks about a16z's investment philosophy of "providing more than just a check," and a recent $500M fund partnered with Lilly.
Not rated yetEpisode 22: Adjuvant Capital's Glenn Rockman
· 1 hr 12 min
Glenn Rockman describes the introduction to impact investing he gained from working for J.P. Morgan and along with the Gates Foundation on the Global Health Investment Fund, and how the idea of investing for public good ultimately sparked Adjuvant Capital in 2019. Armed with a $300M+ fund that was raised from numerous foundations and for-profit funds in 2021, Adjuvant has been investing in public health technologies, post proof of concept, to help accelerate their development and ultimately make them more accessible to those around the world who need them.
Not rated yetEpisode 21: Scion Life Sciences' Aaron Kantoff
· 1 hr 10 min
Aaron Kantoff describes the road on the public markets side that eventually led him to venture, and recalls successful investments he helped lead at firms like Apple Tree Partners and Medicxi, such as Stoke Therapeutics, Akero Therapeutics, Centessa Pharmaceuticals, and RayzeBio. He discusses founding Scion with his partner, Samuel Hall, and describes raising their first fund and how the firm has a longer outlook than is traditionally thought of in venture.
Not rated yetEpisode 20: Breakout Ventures' Lindy Fishburne
· 1 hr 7 min
Lindy Fishburne describes her educational background and career, and transitioning from the philanthropic Breakout Labs within the Thiel Foundation to Breakout Ventures, a traditional venture firm that has a diverse set of limited partners. Plus, how she is navigating these challenging times in healthcare and biotech.
Not rated yetEpisode 19: Longwood Fund's Christoph Westphal
· 1 hr 3 min
Dr. Westphal describes his upbringing and early career at McKinsey and Polaris, founding or co-founding companies like Momenta, Alnylam, Sirtris, Acceleron, and VeraStem, and creating the Longwood Fund. He shares his thoughts on venture investing, the current environment in biotech, focusing on creating new medicines, and his love of the Boston ecosystem.
Not rated yetEpisode 18: Playground Global's Jory Bell
· 1 hr 16 min
Jory Bell shares the details of his expansive educational background and early career, which included being a product designer at Apple during the return of Steve Jobs. He describes Playground's engineering and tech angle to investing in life sciences, and weighs in on sizable seed and pre-seed investments the industry has seen lately that get startups to a proof of concept.
Not rated yetEpisode 17: Norwest Venture Partners' Tiba Aynechi
· 55 min
Tiba Aynechi describes her career path, which has been spent entirely in the Bay Area since she earned her PhD from UCSF in the early 2000's. She describes the value of BD experience she earned while working on licensing deals early in her career, her more than a decade at Novo Ventures, and what appealed to her to join Norwest. Plus, her thoughts on a board of directors' relationship with management teams.
Not rated yetEpisode 16: RA Capital's Josh Resnick
· 1 hr 12 min
Josh Resnick describes his career path, which includes working on the venture side of both private funds and pharma (Merck). He explains the different investment strategies of RA Capital, and talks about how the firm's Raven company building incubator fits in. Plus, his thoughts on venture investing in the current environment.
Not rated yetEpisode 15: Mission BioCapital's Steve Tregay
· 1 hr 1 min
Steve Tregay describes his career path, including how early roles at Array BioPharma and Novartis led him to found Forma Therapeutics. He describes the founding and growth of LabCentral, for which he is still the chairman today, and how getting a look at entrepreneurs at such an early stage naturally led to the investment work that he and his partners do at Mission BioCapital.
Not rated yetEpisode 14: Aditum Bio's Joe Jimenez
· 1 hr 13 min
Joe Jimenez describes the career path in consumer products that led him to pharma, his time running Novartis, and the idea to co-found Aditum Bio with his partner Mark Fishman. He explains Aditum's investment philosophy, and why they like focusing on translational medicine opportunities that are just heading into the clinic. Plus, his thoughts on making R&D more efficient.
Not rated yetEpisode 13: Civilization Ventures' Shahram Seyedin-Noor
· 1 hr 12 min
Shahram describes his upbringing as a refugee from Iran, his early career in law and banking, and how his initial experience in the tech industry has benefitted his eye towards life sciences. He recalls founding Civilization Ventures with an initial $1M fund, and talks about what it has quickly grown into today, Plus, his take on AI and the current state of tech bio.
Not rated yet